Our present study aimed to clarify the expression of TLR9 and the direct effect of CpG ODNs on B-ALL cells to determine whether CpG ODNs can be used as a novel drug that can kill B-ALL cells while improving their immunogenicity. The gene discussed is TLR9; the disease is acute lymphoblastic leukemia.